Page last updated: 2024-08-24

triazoles and crizotinib

triazoles has been researched along with crizotinib in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (90.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Jones, HM; Koudriakova, T; Romero, D; Skaptason, J; Tan, W; Vekich, S; Wilner, KD; Yamazaki, S1
Zhang, HJ; Zhang, L; Zhang, XT1
Acquaviva, J; Bates, RC; Camidge, DR; Doebele, RC; El-Hariry, I; Friedland, JC; He, S; Jiang, Q; Jimenez, JP; Lovly, CM; Morris, SW; Proia, DA; Sang, J; Sequeira, M; Shaw, AT; Smith, DL; Xue, L; Zhang, C1
Beebe, K; Huang, Y; Miyajima, N; Mollapour, M; Neckers, L; Nonomura, K; Rivas, C; Shinohara, N; Sourbier, C; Tatokoro, M; Trepel, JB; Tsutsumi, S; Yoshida, S1
Li, H; Sun, Y; Xu, F1
Back, KR; Docherty, R; Doherty, CL; Feeder, N; Meenan, P; Pidcock, E; Reilly, AM; Sadiq, G1
Ambrogio, C; Bombelli, S; Casati, C; Ceccon, M; Chiarle, R; Compagno, M; Di Giacomo, F; Gambacorti-Passerini, C; Giudici, G; Manazza, AD; Mastini, C; Menotti, M; Merlo, MEB; Mologni, L; Poggio, T; Rigolio, R; Turner, SD; Varesio, LM; Voena, C1
Liu, H; Lu, S; Lu, T; Pan, J; Qiao, X; Xiang, B; Yan, L; Yuan, H; Zhang, L; Zhang, Y1
Chen, KY; Fagin, JA; Ghossein, R; Knauf, JA; Luckett, KA; Socci, ND; Voza, F1
Chen, L; Chen, W; Li, L1

Reviews

1 review(s) available for triazoles and crizotinib

ArticleYear
[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2012, Volume: 41, Issue:12

    Topics: Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Triazoles

2012

Trials

2 trial(s) available for triazoles and crizotinib

ArticleYear
Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:3

    Topics: Administration, Oral; Adult; Animals; Biological Availability; Cells, Cultured; Crizotinib; Dogs; Drug Evaluation, Preclinical; Half-Life; Hepatocytes; Humans; Macaca fascicularis; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Models, Molecular; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Triazoles; Young Adult

2011
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
    Cancer discovery, 2013, Volume: 3, Issue:4

    Topics: Adult; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays; Young Adult

2013

Other Studies

7 other study(ies) available for triazoles and crizotinib

ArticleYear
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.
    Cancer research, 2013, Dec-01, Volume: 73, Issue:23

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cells, Cultured; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Female; HEK293 Cells; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Neoplasms; NIH 3T3 Cells; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Triazoles; Xenograft Model Antitumor Assays

2013
Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
    Biochemical and biophysical research communications, 2014, 11-28, Volume: 454, Issue:4

    Topics: Anaplastic Lymphoma Kinase; Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Crizotinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Neuroblastoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured

2014
The integration of solid-form informatics into solid-form selection.
    The Journal of pharmacy and pharmacology, 2015, Volume: 67, Issue:6

    Topics: Analgesics; Chemistry, Pharmaceutical; Crizotinib; Crystallization; Cyclohexanes; Databases, Factual; Drug Stability; Humans; Hydrogen Bonding; Informatics; Maraviroc; Molecular Conformation; Pharmaceutical Preparations; Pyrazoles; Pyridines; Technology, Pharmaceutical; Triazoles

2015
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
    Oncogene, 2016, 07-21, Volume: 35, Issue:29

    Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Crizotinib; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Histones; Humans; Hydrazines; Lymphoma, Large-Cell, Anaplastic; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Confocal; Nucleophosmin; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; RNA Interference; Signal Transduction; Transplantation, Heterologous; Triazoles

2016
Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.
    Journal of biomolecular structure & dynamics, 2018, Volume: 36, Issue:8

    Topics: Binding Sites; Crizotinib; Humans; Hydrogen Bonding; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Mutation; Protein Binding; Protein Domains; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Triazoles; Tyrosine

2018
Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.
    The Journal of clinical investigation, 2018, 08-31, Volume: 128, Issue:9

    Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Cell Line, Tumor; Coumarins; Crizotinib; Disease Models, Animal; Drug Resistance, Neoplasm; Genes, p53; Humans; Indoles; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mutation, Missense; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Pyrazines; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Triazoles

2018
Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib.
    Clinical pharmacology in drug development, 2022, Volume: 11, Issue:6

    Topics: Antifungal Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Fluconazole; Humans; Itraconazole; Lung Neoplasms; Triazoles; Voriconazole

2022